Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Mark Moasser, MD

    SchoolUCSF School of Medicine
    Address2340 Sutter Street
    San Francisco CA 94115
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Tufts UniversityM.D.School of Medicine1988

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Awarded Grants
      Collapse Clinical Trials

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
        View in: PubMed
      2. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. PMID: 26860947.
        View in: PubMed
      3. Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015 Dec 1; 6(38):41123-33. PMID: 26516700.
        View in: PubMed
      4. Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov 1; 1(8):1154-61. PMID: 26204261.
        View in: PubMed
      5. Amin DN, Ahuja D, Yaswen P, Moasser MM. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015 Dec; 14(12):2805-17. PMID: 26438156.
        View in: PubMed
      6. Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10(4):e0121607. PMID: 25901353; PMCID: PMC4406848.
      7. Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene. 2015 Oct 8; 34(41):5288-94. PMID: 25619841; PMCID: PMC4515412 [Available on 04/08/16].
      8. Campbell MR, Moasser MM. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clin Cancer Res. 2015 Jul 1; 21(13):2886-8. PMID: 25609069; PMCID: PMC4490014 [Available on 07/01/16].
      9. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 1; 33(7):786-809. PMID: 25605863.
        View in: PubMed
      10. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH. A multilevel model of postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2078-92. PMID: 25017248.
        View in: PubMed
      11. Moasser MM. Two dimensions in targeting HER2. J Clin Oncol. 2014 Jul 1; 32(19):2074-7. PMID: 24868026; PMCID: PMC4517047.
      12. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549; PMCID: PMC4017711.
      13. Littlefield P, Moasser MM, Jura N. An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol. 2014 Apr 24; 21(4):453-8. PMID: 24656791; PMCID: PMC4018233.
      14. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 1; 73(3):1168-79. PMID: 23243018; PMCID: PMC3563920.
      15. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 1; 447(3):417-25. PMID: 22853430; PMCID: PMC3722874.
      16. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31. PMID: 21706059; PMCID: PMC3184310.
      17. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 7; 104(12):1828-35. PMID: 21559012; PMCID: PMC3111195.
      18. Spassov DS, Ahuja D, Wong CH, Moasser MM. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011; 6(4):e19154. PMID: 21559459; PMCID: PMC3084758.
      19. Spassov DS, Wong CH, Moasser MM. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32. PMID: 21490433; PMCID: PMC3117134.
      20. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. PMID: 21350003.
        View in: PubMed
      21. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82. PMID: 21189288; PMCID: PMC3028653.
      22. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50. PMID: 20816829; PMCID: PMC2991618.
      23. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 1; 16(5):1373-83. PMID: 20179223; PMCID: PMC2831167.
      24. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. PMID: 20371474; PMCID: PMC3033659.
      25. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
      26. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9. PMID: 19388114; PMCID: PMC4511711.
      27. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65. PMID: 19349359; PMCID: PMC2671264.
      28. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 1; 15(7):2311-22. PMID: 19318475; PMCID: PMC3023342.
      29. Arkin M, Moasser MM. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76. PMID: 19037833; PMCID: PMC3031872.
      30. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7878-83. PMID: 19047117; PMCID: PMC2748748.
      31. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 1; 415(1):97-110. PMID: 18498248; PMCID: PMC3079392.
      32. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008 May; 65(10):1566-84. PMID: 18259690; PMCID: PMC3060045.
      33. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PMID: 18410794.
        View in: PubMed
      34. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. PMID: 17968965; PMCID: PMC3024590.
      35. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec; 13(12):527-34. PMID: 17981505; PMCID: PMC3035105.
      36. Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat. 2008 Sep; 111(2):377-88. PMID: 17952589.
        View in: PubMed
      37. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007 Aug 20; 97(4):453-7. PMID: 17667926; PMCID: PMC2360352.
      38. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007 Oct 11; 26(46):6577-92. PMID: 17486079; PMCID: PMC3071580.
      39. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007 Oct 4; 26(45):6469-87. PMID: 17471238; PMCID: PMC3021475.
      40. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41. PMID: 17206155; PMCID: PMC3025857.
      41. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006 Jul; 54(7):1119-24. PMID: 16866685.
        View in: PubMed
      42. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006 Jun; 54(6):925-31. PMID: 16776787.
        View in: PubMed
      43. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006 Aug; 98(3):343-8. PMID: 16541322.
        View in: PubMed
      44. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11; 24(34):5333-43. PMID: 16007225; PMCID: PMC3023961.
      45. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005 Apr; 6(1):55-60. PMID: 15899073.
        View in: PubMed
      46. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar; 90(2):157-63. PMID: 15803362.
        View in: PubMed
      47. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4062-7. PMID: 15217939.
        View in: PubMed
      48. Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004 Jun; 3(6):796-803. PMID: 15136770.
        View in: PubMed
      49. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 1; 9(12):4340-6. PMID: 14555504.
        View in: PubMed
      50. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. PMID: 12684394.
        View in: PubMed
      51. Moasser MM, Rosen N. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res Treat. 2002 May; 73(2):135-44. PMID: 12088116.
        View in: PubMed
      52. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res. 2001 Dec; 7(12):3934-41. PMID: 11751485.
        View in: PubMed
      53. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 1; 61(19):7184-8. PMID: 11585753.
        View in: PubMed
      54. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15; 19(10):2587-95. PMID: 11352950.
        View in: PubMed
      55. Münster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001 Apr 1; 61(7):2945-52. PMID: 11306472.
        View in: PubMed
      56. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat. 2001 Apr; 66(3):239-48. PMID: 11510695.
        View in: PubMed
      57. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15; 59(24):6145-52. PMID: 10626805.
        View in: PubMed
      58. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1369-74. PMID: 9465021; PMCID: PMC19006.
      59. Moasser MM, Khoo KS, Maerz WJ, Zelenetz A, Dmitrovsky E. Derivation and characterization of retinoid-resistant human embryonal carcinoma cells. Differentiation. 1996 Jul; 60(4):251-7. PMID: 8765055.
        View in: PubMed
      60. Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco AR, Ciardiello F. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. Int J Cancer. 1996 May 16; 66(4):538-43. PMID: 8635871.
        View in: PubMed
      61. Ahn MJ, Langenfeld J, Moasser MM, Rusch V, Dmitrovsky E. Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors. Oncogene. 1995 Dec 7; 11(11):2357-64. PMID: 8570187.
        View in: PubMed
      62. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E. all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 1995 Aug 15; 76(4):680-6. PMID: 8625166.
        View in: PubMed
      63. Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. Oncogene. 1995 Jun 15; 10(12):2307-14. PMID: 7784078.
        View in: PubMed
      64. Moasser MM, Reuter VE, Dmitrovsky E. Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells. Oncogene. 1995 Apr 20; 10(8):1537-43. PMID: 7731708.
        View in: PubMed
      65. Moasser MM, DeBlasio A, Dmitrovsky E. Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor gamma in human teratocarcinomas. Oncogene. 1994 Mar; 9(3):833-40. PMID: 8108126.
        View in: PubMed
      Mark's Networks
      Related Concepts
      Derived automatically from this person's publications.
      People in Profiles who have published with this person.
      Related Authors
      People who share related concepts with this person.
      Back to TOP